Neurosense Therapeutics Ltd Stock Price, News & Analysis

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) reported significant advancements in its clinical trials in Q1 2023. The Phase 2b ALS PARADIGM trial has reached 80% patient enrollment, with completion expected in H1 2023 and topline results anticipated in H2 2023. Concurrently, the company is preparing for a Phase 2 Alzheimer's disease trial, leveraging findings from a biomarker study that indicated elevated TDP-43 levels in Alzheimer's patients. A collaboration with Massachusetts General Hospital has been established for in-vitro studies on PrimeC's effects on ALS pathways. Additionally, results from a Parkinson's disease biomarker study are expected by early May. CEO Alon Ben-Noon emphasized the potential of NeuroSense's combination drug platform in addressing severe neurodegenerative diseases.

NeuroSense Therapeutics (NASDAQ: NRSN) has announced a collaboration with Dr. Ghazaleh Sadri-Vakili's NeuroEpigenetics Lab at Massachusetts General Hospital to study PrimeC, its lead ALS drug candidate. The research will utilize an in vitro model derived from post-mortem ALS brain tissue to examine PrimeC's neurotherapeutic effects, specifically targeting pathways related to TDP-43 accumulation and mitochondrial dysfunction. Preliminary findings will be presented by Dr. Zimri at the AD/PD 2023 Conference in Gothenburg, Sweden, scheduled for March 28 - April 1, 2023. PrimeC has previously shown promise in a Phase 2a clinical trial.

NeuroSense Therapeutics (NASDAQ: NRSN) announced that Dr. Shiran Zimri will present findings related to PrimeC at the AD/PD 2023 Conference in Gothenburg, Sweden, from March 28 - April 1, 2023. PrimeC is currently in Phase 2b trials for ALS, with topline results anticipated in H2 2023. Initial studies show PrimeC's efficacy in improving ALS-related biomarkers and tolerability. Additionally, a Phase 2 proof-of-concept study for Alzheimer's Disease is set to commence in H1 2023, focusing on the combined therapeutic strategy using ciprofloxacin and celecoxib, which may show promise in treating AD based on biomarker detections.

NeuroSense Therapeutics (Nasdaq: NRSN) announced its annual report for 2022, showcasing significant developments in its clinical trials and financials. The company is advancing its lead candidate PrimeC for ALS, with over 50% patient enrollment in the Phase 2b PARADIGM trial, expected to report topline results in H2 2023. Positive preliminary findings from a biomarker study in Alzheimer's disease prompted plans for a Phase 2 trial in H1 2023. However, R&D expenses surged by 108% to $6.4 million, and general administrative costs increased by 185% to $7.1 million, reflecting expanding operational activities. Cash reserves stood at $7.1 million.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced participation in the 17th annual BIO-Europe Spring conference on March 20-22, 2023 in Basel, Switzerland. Chief Medical Officer Dr. Ferenc Tracik and VP of Business Development Nedira Salzman-Frenkel will meet potential partners regarding the company's drug development pipeline. NeuroSense's lead drug, PrimeC, is in a global Phase 2b study for ALS, with results expected in H2 2023. Other programs include Alzheimer's and Parkinson's disease treatments, with key milestones expected in 2023.